70 citations
,
September 2017 in “Expert opinion on therapeutic patents” The review suggests that while many AKR1C3 inhibitors show promise for treating certain cancers, more research is needed to confirm their effectiveness in humans.
December 2025 in “Journal of health economics and outcomes research” Alopecia areata in Saudi Arabia is costly, mainly due to lost productivity and drug costs.
December 2025 in “Actas Dermo-Sifiliográficas” Ritlecitinib is effective and safe for treating severe alopecia areata in people aged 12 and older.
1 citations
,
November 2024 in “Expert Opinion on Drug Safety” This study analyzed 7,933 adverse event reports related to aromatase inhibitors (AIs) from the FDA Adverse Event Reporting System, covering data from 2004 to 2023. It identified 642 positive signals of adverse reactions, with specific concerns for each AI: anastrozole was linked to antiphospholipid syndrome, plantar fasciitis, and autoimmune pancreatitis; letrozole was associated with androgenetic alopecia, myosclerosis, and pneumonic herpes virus; exemestane was connected to infection reactivation, decreased thyroxine free, and atrial dilatation. Letrozole had the earliest onset of adverse events, followed by exemestane and anastrozole. The study underscores the importance of monitoring these adverse events in real-world clinical settings.
December 2023 in “International Journal of Research in Ayurveda and Pharmacy” Ayurvedic remedies may boost immunity and balance in cancer treatment but need more research.
December 2025 in “Current Issues in Molecular Biology” Cytarabine can cause multiple organ toxicities, especially neurotoxicity, but better research methods are needed to fully understand and predict these effects.
March 2026 in “American Journal of Clinical Dermatology” Ritlecitinib is effective and safe for long-term use in treating severe alopecia areata in people aged 12 and older.
18 citations
,
January 2013 in “Evidence-based Complementary and Alternative Medicine” Aconiti Lateralis Preparata Radix helps mouse stem cells grow and turn into bone cells faster than usual methods.
September 2025 in “Dermatology and Therapy” Baricitinib is a promising treatment for alopecia areata in the UAE, but there are challenges with data and access.
July 2025 in “Malaria Journal” Resolving malaria-related lung issues doesn't rely on Alox12 and leaves some inflammation.
December 2023 in “Journal of health and rehabilitation research” Oral Apremilast effectively treats alopecia areata in most patients.
April 2016 in “Journal of Investigative Dermatology” Mefloquine, an antimalarial drug, is effective in killing melanoma cells resistant to other treatments by causing lethal stress in the cells.
December 2025 in “International Journal of Innovative Technologies in Social Science” Ritlecitinib is generally safe for long-term use, with mostly mild side effects.
Ritlecitinib significantly regrows scalp hair in people with alopecia areata.
February 2012 in “Hospital Pharmacy” 3 citations
,
January 2011 in “Yearbook of Dermatology and Dermatologic Surgery” 13 citations
,
February 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib shows promise for treating alopecia areata, especially with early and extended treatment.
1 citations
,
September 2001 in “PubMed” Acitretin treats severe skin conditions but requires careful monitoring due to serious side effects.
January 2010 in “Yearbook of Endocrinology” Two new compounds can block androgen receptor activity in different ways and may lead to new treatments for androgen-related diseases.
June 2025 in “British Journal of Dermatology” Ruxolitinib helped a woman with a genetic mutation regrow her hair and improved her health.
January 2004 in “Indian Journal of Nephrology” July 2025 in “Revista Eletrônica Acervo Científico” Hydroxychloroquine is most effective for scarring alopecias, especially when combined with other treatments.
8 citations
,
June 2023 in “European Journal of Endocrinology” The inhibitor affects androgen metabolism but not ovarian function.
January 2021 in “International journal of basic and clinical pharmacology” Hydroxychloroquine is less effective than betamethasone oral mini pulse therapy for treating alopecia areata.
48 citations
,
July 2023 in “Pediatric Dermatology” Ritlecitinib effectively regrows hair in adolescents with alopecia areata and is safe.
2 citations
,
April 2023 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” JAK-inhibitors for alopecia areata are generally safe with mostly mild side effects and a low rate of treatment withdrawal.
December 2025 in “Journal of health economics and outcomes research” Alopecia Areata in Saudi Arabia is costly, mainly due to lost work and medication expenses, needing better diagnosis, treatment, and care.
10 citations
,
March 2022 in “Healthcare” Mineralocorticoid receptor antagonist therapy does not significantly reduce mortality in COVID-19 patients.
13 citations
,
April 2020 in “European Journal of Dermatology” Apremilast showed mixed results for treating severe alopecia areata.